Fenghuang Zhan
Professor
Also affiliated: Tongji University (2014); University of Iowa (2012–2023); University of Maryland, Baltimore (2003); University of Minnesota (2013); Pennsylvania State University (2013); Hackensack University Medical Center (2003); Mayo Clinic (2005–2009); The University of Texas MD Anderson Cancer Center (2009); Harvard University (2003); Central South University (2023); University of Alberta (2004); Inserm (2002–2003); Duke University (2009); University of Basel (2005); Chinese Academy of Medical Sciences & Peking Union Medical College (2016–2019); National and Kapodistrian University of Athens (2009); Medical College of Wisconsin (2003); Cornell University (2001–2009); University of Utah (2008–2013); University of Arkansas Medical Center (2005–2024); Huntsman Cancer Institute (2009–2011); University of Iowa Hospitals and Clinics (2012–2019); Aarhus University Hospital (2002); Yale University (2009); Universitätsklinikum Erlangen (2003); Fred Hutch Cancer Center (2002); Centre Hospitalier Universitaire de Montpellier (2003); Cancer Research And Biostatistics (2003–2007); Hôpital Gui de Chauliac (2002); Myeloma UK (2007); Mayo Clinic in Arizona (2005–2009); Duke Medical Center (2009); Hainan General Hospital (2024); Hôpital Lapeyronie (2002); Shanghai Tenth People's Hospital (2014); Dana-Farber/Harvard Cancer Center (2003); National Cancer Institute (2001–2007); University of Iowa Health Care (2013–2020); Hôpital Saint Eloi (2003); Institute of Hematology & Blood Diseases Hospital (2016–2019); The US Oncology Network (2009); Ospedale San Bortolo (2009); Celgene (United States) (2009); University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center (2003); University of Iowa Holden Comprehensive Cancer Center (2013–2020); Masonic Cancer Center (2013); State Key Laboratory of Experimental Hematology (2016–2019); Cross Cancer Institute (2004); AbbVie Biotherapeutics (United States) (2009); Penn State Milton S. Hershey Medical Center (2013)
Internal Med, College of Medicine
Research Areas
Biomedical Subjects
Biography and Research Information
OverviewAI-generated summary
Fenghuang Zhan's research focuses on understanding the molecular mechanisms and genetic underpinnings of multiple myeloma, a cancer of plasma cells. His work investigates gene expression patterns, chromosomal abnormalities, and signaling pathways involved in the development and progression of the disease. This includes examining the role of specific genes and pathways, such as Wnt signaling, NF-κB, and cyclin D, in the formation of osteolytic lesions and overall disease risk.
Dr. Zhan's research has also explored therapeutic targets and diagnostic models for multiple myeloma. He has investigated potential new antibody targets and developed gene expression models to classify high-risk disease, correlating genetic findings with patient prognosis and outcomes following treatment. His work contributes to the characterization of drug resistance mechanisms in multiple myeloma, aiming to improve therapeutic strategies.
With an h-index of 68 and over 19,000 citations, Dr. Zhan is recognized for his significant contributions to the field. He has served as PI on multiple NIH grants, including one for $507,317, focused on understanding drug resistance in multiple myeloma. His extensive publication record includes collaborations with numerous researchers at the University of Arkansas for Medical Sciences, such as John D. Shaughnessy, Guido Tricot, and Maurizio Zangari.
Metrics
- h-index: 68
- Publications: 428
- Citations: 19,565
Positions
-
Professor publications 2001–2026University of Arkansas for Medical Sciences Internal Med, College of Medicine Institutional directory
Selected Publications
-
Abstract LB220: Can dietary calcium prevent myeloma onset (2026)
-
Clinical outcomes and risk factors of cytomegalovirus reactivation in teclistamab-treated multiple myeloma patients (2026)
-
Peripheral blood immune cell profiling and response to BCMA CAR-T cell therapy in relapsed refractory multiple myeloma (2026)
-
Proinflammatory GSDMD activation in live macrophages and DLBCL cells marks cognate interactions and better prognosis (2025)
-
Polyclonal plasma cell (PolyPC) signature as a key indicator for predicting the progression of MGUS to multiple myeloma (2025)
-
International Myeloma Society/International Myeloma Working Group Consensus Recommendations on the Definition of High-Risk Multiple Myeloma (2025)
-
Long-Term Follow-Up of Patients With Multiple Myeloma Treated on Earlier Total Therapy Protocols (2025)
-
Cystatin M/E Ameliorates Multiple Myeloma-Induced Hyper Osteolytic Bone Resorption (2025)
-
Prior exposure to belantamab mafodotin influences outcomes with idecabtagene vicleucel in patients with multiple myeloma (2025)
-
Targeting caseinolytic mitochondrial matrix peptidase, a novel contributor to the pathobiology of high-risk multiple myeloma (2025)
-
Single-cell analysis of neoplastic plasma cells identifies myeloma pathobiology mediators and potential targets (2025)
-
Long-term follow-up of Total Therapy IV: a phase 3 clinical trial for standard-risk multiple myeloma (2024)
-
Multi-Omics Reveal Immune Microenvironment Alterations in Multiple Myeloma and Its Precursor Stages (2024)
-
Prior Exposure to Belantamab Mafodotin Influences Outcomes with Idecabtagene Vicluecel in Patients with Multiple Myeloma (2024)
-
Multi-omics reveal immune microenvironment alterations in multiple myeloma and its precursor stages (2024)
Federal Grants 2 $507,317 total
Grants & Funding
As listed on this researcher's institutional profile. Federal awards with verified records are shown above.
- NEK2 Over-expression Causes Drug Resistance in Myeloma NIH Principal Investigator
- Biological Validation of Candidate Myeloma Driver Genes NIH/Nat. Cancer Institute via Medical College of Wisconsin Principal Investigator
- Novel NEK2 signaling pathways in myeloma progression NIH Principal Investigator
- Gene expression profiling vs MRD assessment in Myeloma NIH Co-Investigator
- U54 - Administrative Core NIH/Nat. Cancer Institute via Baylor College of Medicine Principal Investigator
- Center for Molecular Interactions in Cancer (CMIC) NIH Co-Investigator
- U54 - Bioinformatics Core NIH/Nat. Cancer Institute via Baylor College of Medicine Principal Investigator
- Targeting NEK2 Enables Immune Checkpoint Blockade in High-Risk/Relapsed Myeloma The Paula and Rodger Riney Foundation Principal Investigator
- Toward improvement of BCMA/CST6-CAR-T therapy to target both myeloma cells and bone resorption Leukemia & Lymphoma Society Principal Investigator
- CD24 Tumor-Initiating Cell as a Novel Therapeutic Target in Myeloma US Department of Defense Principal Investigator
- Project 1 – Prevention of MGUS progression to MM by modulating the bone marrow microenvironment NIH/Nat. Cancer Institute via Baylor College of Medicine Principal Investigator
- Retinoid Based Treatment Approaches to Target the Myeloma Stem Cell NIH Principal Investigator
Collaboration Network
Top Collaborators
- The molecular classification of multiple myeloma
- Frequent Engagement of the Classical and Alternative NF-κB Pathways by Diverse Genetic Abnormalities in Multiple Myeloma
- A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1
- Cyclin D dysregulation: an early and unifying pathogenic event in multiple myeloma
- Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance, and normal bone marrow plasma cells
Showing 5 of 94 shared publications
- The molecular classification of multiple myeloma
- A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1
- Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance, and normal bone marrow plasma cells
- CS1, a Potential New Therapeutic Antibody Target for the Treatment of Multiple Myeloma
- Frequent gain of chromosome band 1q21 in plasma-cell dyscrasias detected by fluorescence in situ hybridization: incidence increases from MGUS to relapsed myeloma and is related to prognosis and disease progression following tandem stem-cell transplantation
Showing 5 of 62 shared publications
- The molecular classification of multiple myeloma
- A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1
- Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance, and normal bone marrow plasma cells
- Gene-expression signature of benign monoclonal gammopathy evident in multiple myeloma is linked to good prognosis
- The molecular make up of smoldering myeloma highlights the evolutionary pathways leading to multiple myeloma
Showing 5 of 53 shared publications
- The molecular classification of multiple myeloma
- Frequent Engagement of the Classical and Alternative NF-κB Pathways by Diverse Genetic Abnormalities in Multiple Myeloma
- A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1
- Cyclin D dysregulation: an early and unifying pathogenic event in multiple myeloma
- Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance, and normal bone marrow plasma cells
Showing 5 of 47 shared publications
- The molecular make up of smoldering myeloma highlights the evolutionary pathways leading to multiple myeloma
- Risk of infections associated with the use of bispecific antibodies in multiple myeloma: a pooled analysis
- Geographic and Racial Disparities in Access to Chimeric Antigen Receptor–T Cells and Bispecific Antibodies Trials for Multiple Myeloma
- Bispecific BCMA/CD24 CAR-T cells control multiple myeloma growth
- Multi-omics reveal immune microenvironment alterations in multiple myeloma and its precursor stages
Showing 5 of 45 shared publications
- The molecular make up of smoldering myeloma highlights the evolutionary pathways leading to multiple myeloma
- Risk of infections associated with the use of bispecific antibodies in multiple myeloma: a pooled analysis
- Geographic and Racial Disparities in Access to Chimeric Antigen Receptor–T Cells and Bispecific Antibodies Trials for Multiple Myeloma
- Bispecific BCMA/CD24 CAR-T cells control multiple myeloma growth
- Multi-omics reveal immune microenvironment alterations in multiple myeloma and its precursor stages
Showing 5 of 44 shared publications
- The molecular classification of multiple myeloma
- A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1
- Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance, and normal bone marrow plasma cells
- Frequent gain of chromosome band 1q21 in plasma-cell dyscrasias detected by fluorescence in situ hybridization: incidence increases from MGUS to relapsed myeloma and is related to prognosis and disease progression following tandem stem-cell transplantation
- Gene-expression signature of benign monoclonal gammopathy evident in multiple myeloma is linked to good prognosis
Showing 5 of 39 shared publications
- Risk of infections associated with the use of bispecific antibodies in multiple myeloma: a pooled analysis
- Geographic and Racial Disparities in Access to Chimeric Antigen Receptor–T Cells and Bispecific Antibodies Trials for Multiple Myeloma
- Bispecific BCMA/CD24 CAR-T cells control multiple myeloma growth
- Multi-omics reveal immune microenvironment alterations in multiple myeloma and its precursor stages
- Risk of Infections Associated with the Use of Bispecific Antibodies in Multiple Myeloma: A Pooled Analysis
Showing 5 of 36 shared publications
- Bispecific BCMA/CD24 CAR-T cells control multiple myeloma growth
- Multi-omics reveal immune microenvironment alterations in multiple myeloma and its precursor stages
- High NEK2 expression in myeloid progenitors suppresses T cell immunity in multiple myeloma
- A gene signature can predict risk of MGUS progressing to multiple myeloma
- CGO: utilizing and integrating gene expression microarray data in clinical research and data management
Showing 5 of 22 shared publications
- FOXM1 regulates glycolysis and energy production in multiple myeloma
- Bispecific BCMA/CD24 CAR-T cells control multiple myeloma growth
- Multi-omics reveal immune microenvironment alterations in multiple myeloma and its precursor stages
- CST6 suppresses osteolytic bone disease in multiple myeloma by blocking osteoclast differentiation
- Bispecific CAR-T Cells Targeting Both BCMA and CD24: A Potentially Treatment Approach for Multiple Myeloma
Showing 5 of 22 shared publications
- The molecular make up of smoldering myeloma highlights the evolutionary pathways leading to multiple myeloma
- Bispecific BCMA/CD24 CAR-T cells control multiple myeloma growth
- Multi-omics reveal immune microenvironment alterations in multiple myeloma and its precursor stages
- Monitoring treatment response and disease progression in myeloma with circulating cell‐free DNA
- CST6 suppresses osteolytic bone disease in multiple myeloma by blocking osteoclast differentiation
Showing 5 of 19 shared publications
- Bispecific BCMA/CD24 CAR-T cells control multiple myeloma growth
- Multi-omics reveal immune microenvironment alterations in multiple myeloma and its precursor stages
- High NEK2 expression in myeloid progenitors suppresses T cell immunity in multiple myeloma
- A gene signature can predict risk of MGUS progressing to multiple myeloma
- Gene expression profiles of primary HPV16- and HPV18-infected early stage cervical cancers and normal cervical epithelium: identification of novel candidate molecular markers for cervical cancer diagnosis and therapy
Showing 5 of 18 shared publications
- Bispecific BCMA/CD24 CAR-T cells control multiple myeloma growth
- Multi-omics reveal immune microenvironment alterations in multiple myeloma and its precursor stages
- Development and validation of an individualized and weighted Myeloma Prognostic Score System ( MPSS ) in patients with newly diagnosed multiple myeloma
- High NEK2 expression in myeloid progenitors suppresses T cell immunity in multiple myeloma
- A gene signature can predict risk of MGUS progressing to multiple myeloma
Showing 5 of 18 shared publications
- FOXM1 regulates glycolysis and energy production in multiple myeloma
- Bispecific BCMA/CD24 CAR-T cells control multiple myeloma growth
- Multi-omics reveal immune microenvironment alterations in multiple myeloma and its precursor stages
- CST6 suppresses osteolytic bone disease in multiple myeloma by blocking osteoclast differentiation
- Bispecific CAR-T Cells Targeting Both BCMA and CD24: A Potentially Treatment Approach for Multiple Myeloma
Showing 5 of 17 shared publications
- The molecular classification of multiple myeloma
- A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1
- Cyclin D dysregulation: an early and unifying pathogenic event in multiple myeloma
- Frequent gain of chromosome band 1q21 in plasma-cell dyscrasias detected by fluorescence in situ hybridization: incidence increases from MGUS to relapsed myeloma and is related to prognosis and disease progression following tandem stem-cell transplantation
- Heparanase Enhances Syndecan-1 Shedding
Showing 5 of 16 shared publications
Similar Researchers
Based on overlapping research topics